Figure 1. Overall survival and event-free survival of the 2837 NHL patients treated with the ACVBP regimen, with a median follow-up of 74 months.
Figure 1.

Overall survival and event-free survival of the 2837 NHL patients treated with the ACVBP regimen, with a median follow-up of 74 months.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal